Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Lipidemic profile of women treated with adjuvant exemestane therapy not significantly altered
November 10th, 2005
The lipidemic profile of women treated with adjuvant exemestane therapy does not appear to be significantly altered following years of tamoxifen therapy. "Long-term endocrine therapy for breast cancer may have clinical implications as drugs that potentially alter the lipid profile may increase the risk of developing cardiovascular disease," investigators in Greece reported. "In a companion subprotocol to the ATENA (Adjuvant post-Tamoxifen Exemestane versus Nothing Applied) trial," C. Markopoulos and colleagues "compared the effect of the steroidal aromatase inactivator exemestane on the lipid profile of post-menopausal women with operable breast...
Source: Women's Health Weekly (2005-11-10)
|
